Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial

Conclusions. Both candidate VLP vaccines were well tolerated and elicited robust immune responses by 7–10 days that persisted through day 28. The 15/50 formulation displayed the best balance of tolerability and immunogenicity. Clinical Trials Registration. NCT02142504.

http://jid.oxfordjournals.org/cgi/content/short/214/6/845?rss=1

Source: The Journal of Infectious Diseases - August 23, 2016 Category: Infectious Diseases Authors: Atmar, R. L., Baehner, F., Cramer, J. P., Song, E., Borkowski, A., Mendelman, P. M., on behalf of the NOR-201 Study Group, on Behalf of the NOR-201 Study Group, Al-Ibrahim, Bernstein, Brandon, Chu, Davis, Epstein, Frey, Rosen, Treanor Tags: VIRUSES Source Type: research